Sincere Co. Ltd.

Sincere Co. Ltd.

7782.T
Sincere Co. Ltd.JP flagTokyo Stock Exchange
455.00
JPY
-6.00
- -
2.97BMarket Cap
Sincere Co. Ltd.
7782.T
(Tokyo Stock Exchange)

Recent

price

455.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
658.54
270.14
863.8
646.09
625.96
703.72
674.46
727.06
887.86
941.79
1,023.91
- -
945.12
Revenue per Share
38.17
13.48
29.76
32.6
2.37
12.29
22.92
13.39
10.5
46.68
47.25
- -
35.23
Basic EPS, GAAP
-69.2
-4.36
105.65
9.73
-7.04
28.42
40.84
-72.86
-49.88
32.29
63.23
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
9.73
12.25
1.98
4
12.99
4.97
3.98
13.89
- -
- -
Dividend per Share
214.41
90.82
262.66
286.15
277.91
309.44
328.27
325.62
323.39
364.1
394.2
- -
364.09
Book Value per Share
283.1
105.31
353.15
344.78
271.47
302.5
315.72
324.24
308.14
325.04
320.69
- -
324.91
Tangible Book Value per Share
6
16
6
7
7
6
6
6
6
6
6
- -
6
Basic Weighted Avg Shares
3,732
4,244
4,921
4,343
4,183
4,369
4,188
4,557
5,586
5,961
6,539
7,456
5,998
Sales/Revenue/Turnover
4.42
4.79
11.76
6.22
0.31
3.29
5.01
2.31
2.69
6.32
7.41
7.03
6.38
Operating Margin (%)
6
8
11
14
10
10
14
11
11
14
80
95
- -
Depreciation Expense
216
212
170
219
16
76
142
84
66
295
302
264
224
Net Income, GAAP
44.57
35.64
33.7
35.46
12.26
50.08
34.04
30.42
41.4
33.8
34
41.22
39.25
Effective Tax Rate (%)
5.8
4.99
3.44
5.05
0.38
1.75
3.4
1.84
1.18
4.96
4.61
3.55
3.73
Profit Margin (%)
1,525
1,464
1,905
2,175
1,728
2,065
2,016
2,373
2,387
2,815
2,596
2,632
2,666
Working Capital
117
57
17
- -
- -
195
135
395
539
779
683
465
792
LT Debt
1,614
1,663
2,026
2,333
1,829
1,888
1,968
2,040
1,988
2,484
2,697
2,819
2,667
Total Equity
- -
4.72
15.17
7.04
0.46
3.03
5.7
2.8
2.97
6.21
6.59
6.44
5.33
Return on Invested Capital (%)
- -
9.68
8.67
11.45
1.05
3.34
5.99
3.29
2.33
7.72
6.61
6.13
5.58
Return on Capital (%)
- -
16.03
11.6
12.82
0.84
4.04
7.19
4.11
3.24
13.62
12.51
10.21
9.97
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
1,520
1,368
1,368
LT Borrowings
779
852
792
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
3,390
3,249
2,894

Working Capital

FRC

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
4,933
4,500
4,771
Cash, Cash Equivalents & STI
2,194
1,683
2,046
Accounts Receivable, Net
1,097
1,035
933
Inventories
1,057
1,057
989
Total Current Liabilities
2,118
1,878
2,105
Payables & Accruals
- -
- -
- -
ST Debt
1,520
1,368
1,368
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.2%
7.83%
4.51%
Free Cash Flow
-206.31%
-78.28%
-12.45%
Net Income, GAAP
65.92%
54.92%
-12.4%
Sales/Revenue/Turnover
6.26%
12.36%
14.02%
Total Cash Common Dividend
- -
87.28%
36.9%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,523
1,566
- -
- -
6,539
2025
- -
- -
- -
- -
7,456
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.43
- -
- -
- -
47.25
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
13.89
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Sincere Co., Ltd. engages primarily in the manufacture and distribution of high-quality contact lenses, with a significant focus on medical contact lenses prescribed by ophthalmologists. Its product portfolio includes daily disposable lenses such as the flagship "Sincere One Day S" line, launched in 2019, along with color lenses targeted at both B2B OEM customers and retail markets. The company also provides comprehensive regulatory support services for medical devices, quasi-drugs, and cosmetics, especially assisting overseas manufacturers in obtaining approvals from Japan's Ministry of Health, Labour and Welfare. Sincere Co., Ltd. operates extensively within Japan and maintains partnerships across Asia, including China, Taiwan, and Korea, emphasizing both domestic market consolidation and strategic overseas expansion. In recent developments, Sincere Co., Ltd. has accelerated its contact lens business growth while strategically shifting towards strengthening its B2B OEM manufacturing model rather than competing directly in the increasingly crowded color lens retail market. The company also expanded its service offerings by enhancing consultation and regulatory advisory services for domestic and foreign contact lens manufacturers seeking entry into the Japanese market. Furthermore, Sincere emphasizes innovation in high-value-added products with enhanced profitability and has adopted new operational systems to reduce manpower reliance. These moves are part of its broader strategy to sustain competitive advantage and expand market share while managing currency exchange impacts and import logistics. Founded in 1969 and headquartered in Japan, Sincere Co., Ltd. operates within the medical devices and eye care industry segment. The company has developed a comprehensive sales distribution network that targets not only first-time contact lens users, ranging from children to the elderly via ophthalmologists, but also drugstore channels and inbound demand markets. Sincere's strategic alliances and ongoing partnerships across Asia underline its intent to build a robust global presence while maintaining its leadership in the Japanese medical lens market. Besides the core contact lens business, the company actively provides consulting services to facilitate regulatory and market entry for foreign companies in Japan, positioning itself as a key industry bridge and advisor. This dual focus on manufacturing and consultancy enhances its profile in a competitive market landscape, ensuring diversified revenue streams. The company’s fabless manufacturing model, leveraging partnerships with global factories, further supports its operational flexibility and cost efficiency. Overall, Sincere Co., Ltd. solidifies its reputation as a specialist in medical contact lenses and related regulatory services, leveraging innovation, strategic partnerships, and market expansion initiatives to maintain growth and profitability in the evolving eye care sector. These recent strategic changes have enabled it to navigate a competitive environment while building a sustainable business foundation.